Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0P2QO
|
||||
| Former ID |
DIB010332
|
||||
| Drug Name |
S-15535
|
||||
| Synonyms |
1-(1,4-Benzodioxan-5-yl)-4-(indan-2-yl)piperazine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Anxiety disorder [ICD9: 300, 311; ICD10:F32, F40-F42] | Phase 2 | [1], [2] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H24N2O2
|
||||
| InChI |
InChI=1S/C21H24N2O2/c1-2-5-17-15-18(14-16(17)4-1)22-8-10-23(11-9-22)19-6-3-7-20-21(19)25-13-12-24-20/h1-7,18H,8-15H2
|
||||
| InChIKey |
QJPPEMXOOWNICQ-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
10243194, 14900073, 26753615, 26753616, 29215165, 29310835, 48179689, 48253921, 57344259, 79460343, 85209810, 90340566, 103232002, 104378207, 121361753, 125820975, 134221970, 135087833, 135650960, 135651202, 136350534, 140448560, 144239784, 162223633, 162312694, 162793530, 163564828, 175612588, 179235771, 184538700, 204360580, 224956703, 227839306, 245590360, 252322750, 252815017
|
||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 1A receptor | Target Info | Antagonist | [3], [4] | |
| KEGG Pathway | cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Serotonergic synapse | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| 5HT1 type receptor mediated signaling pathway | |||||
| Reactome | Serotonin receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | ||||
| SIDS Susceptibility Pathways | |||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 26). | ||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002186) | ||||
| REF 3 | S 15535, a benzodioxopiperazine acting as presynaptic agonist and postsynaptic 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine. Br J Pharmacol. 1999 Nov;128(6):1207-14. | ||||
| REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.